IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization.
研究概览
简要总结
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.
Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age > 18 and < 70 years
- •IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion
- •Glomerular filtration rate (MDRD formula as simplified) < 90 ml/mn and > 30 ml/mn/1,73 m2
- •Consent form signed
排除标准
- •Patients with cirrhosis or chronic liver disease
- •Patients with a history of Crohn's disease or celiac disease
- •Patients who received treatment with corticosteroids or affiliates for six months
- •Patients who received a live attenuated vaccine during the past 4 weeks
- •Patients with a known infection such as HIV, hepatitis B or C
- •Patients who presented with a serious infection during the last month
- •Breastfeeding women
- •Patients not affiliated with a social security scheme
- •Under guardianship patient
结局指标
主要结局
The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization.
时间窗: 30 minutes
次要结局
- The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory(30 minutes)